Biolase announces delisting from Nasdaq

Biolase announced that the company received a notice from Nasdaq that it has determined to delist the shares of the company’s common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq’s $2,500,000 minimum stockholders’ equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b). Suspension of trading in the company’s common stock on the Nasdaq exchange will be effective at the open of trading on June 20, 2024.